[Ala113]-MBP (104-118)

[Ala113]-MBP (104-118) is a synthetic peptide derivative corresponding to a segment of the myelin basic protein (MBP), with an alanine substitution at position 113. As a specialized research reagent, this peptide is designed to model post-translational modifications and sequence variations within the immunodominant region of MBP, a protein integral to the structure and function of the myelin sheath in the central nervous system. The sequence modification in [Ala113]-MBP (104-118) enables researchers to dissect the structural and immunological consequences of single amino acid substitutions within a critical epitope, providing a valuable tool for probing the molecular basis of protein-protein interactions, antigen presentation, and immune recognition associated with myelin proteins.

Epitope mapping: The modified peptide is widely employed in epitope mapping studies to delineate the specific residues within the MBP 104-118 region that are recognized by T cells or antibodies. By comparing immune responses elicited by the wild-type and alanine-substituted sequences, researchers can identify critical contact points for antigen recognition, advancing the understanding of autoimmune mechanisms and the specificity of immune responses to myelin antigens.

Autoimmunity research: [Ala113]-MBP (104-118) serves as a model antigen in investigations of T cell-mediated autoimmunity, particularly in experimental systems modeling demyelinating diseases. Its defined sequence and site-specific substitution allow for precise analysis of how alterations in MBP epitopes affect T cell activation, tolerance, and cross-reactivity. Such studies are instrumental in elucidating the molecular triggers of aberrant immune responses against myelin components.

Peptide-MHC binding assays: The alanine substitution at position 113 enables detailed studies of peptide-major histocompatibility complex (MHC) interactions. By assessing the binding affinity and stability of the modified peptide with various MHC class II molecules, researchers can clarify the structural requirements for antigen presentation and the impact of sequence variation on MHC restriction. This approach aids in characterizing the molecular determinants of immunodominance and susceptibility to immune recognition.

Structural and conformational analysis: The availability of [Ala113]-MBP (104-118) supports investigations into the conformational dynamics of MBP epitopes. Techniques such as circular dichroism, NMR spectroscopy, or computational modeling can be applied to compare the secondary structure and flexibility of the alanine-substituted peptide with its native counterpart. Insights gained from such studies inform the relationship between peptide structure, antigenicity, and immune recognition.

Peptide synthesis and assay development: As a well-defined synthetic peptide, [Ala113]-MBP (104-118) is also utilized as a standard or control in the development and validation of peptide-based assays. Its sequence specificity and chemical stability make it suitable for use in quantitative immunoassays, screening platforms, or quality control procedures, facilitating reproducibility and accuracy in experimental workflows involving myelin protein fragments.

1. An interdomain binding site on HIV-1 Nef interacts with PACS-1 and PACS-2 on endosomes to down-regulate MHC-I

2. Genetic, cellular, and structural characterization of the membrane potential-dependent cell-penetrating peptide translocation pore

3. Constitutive and inflammation-dependent antimicrobial peptides produced by epithelium are differentially processed and inactivated by the commensal Finegoldia magna and the pathogen Streptococcus pyogenes

4. The spatiotemporal control of signalling and trafficking of the GLP-1R

5. Uncarboxylated osteocalcin decreases insulin-stimulated glucose uptake without affecting insulin signaling and regulators of mitochondrial biogenesis in myotubes